Autoantibodies against cardiac troponin i in patients with congestive heart failure

European Journal of Heart Failure

Volumn 12, Issue 7, 2010, Pages 668-675

  Düngen, Hans Dirk ^a   Platzeck, Maria ^a   Vollert, Jörn ^a   Searle, Julia ^a   Müller, Christian ^b   Reiche, Janett ^b   Mehrhof, Felix ^a   Müller, Reinhold ^c   Möckel, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Clinical Chemistry   (Germany)

^c JAMES COOK UNIVERSITY   (Australia)

Author keywords

Autoantibodies; Biomarkers; Heart failure; NT proBNP; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; TROPONIN I; BIOLOGICAL MARKER;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIAC PATIENT; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYSTOLIC BLOOD PRESSURE; VALVULAR HEART DISEASE; BLOOD; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART MUSCLE; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; TROPONIN I;

EID: 77954940822     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq088     Document Type: Article

References (31)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018.
2. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. Eur Heart J 1997;18:208-225.
3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93: 1137-1146.
4. Dickstein K, Cohen-Solal A, Filippatos G, McMurray J, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008;29:2388-2442.
5. Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, Turner RM, Poole-Wilson PA, Davis SW, Sutton GC. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001;22:228-236.
6. Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittrich S, Blaudeck N, Hardt SE, Pfitzer G, Rose NR, Katus HA, Kaya Z. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006;114:1693-1702.
7. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291:319-322.
8. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9:1477-1483.
9. Eriksson S, Hellman J, Pettersson K. Autoantibodies against cardiac troponins. N Engl J Med 2005;352:98-100.
10. Shmilovich H, Danon A, Binah O, Roth A, Chen G, Wexler D, Keren G, George J. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. Int J Cardiol 2007;117:198-203.
11. Miettinen KH, Eriksson S, Magga J, Tuomainen P, Kuusisto J, Vanninen EJ, Turpeinen A, Punnonen KR, Pettersson K, Peuhkurinen KJ. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardio-myopathy. J Card Fail 2008;14:481-488.
12. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402. (Pubitemid 35239711)
13. Lainchbury JGCE, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728-735.
14. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid Measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
15. Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
16. Dungen H, Apostolovic S, Inkrot S, Tahirovic E, Karckhardt F, Pavlovic M, Putnikovic B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel K-J, Dietz R. Biso-prolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 2008;97:578-586.
17. Cleland JG, Coletta AP, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology heart failure meeting 2009: chance, B-convinced, CHAT, CIBIS-ELD, and signal-HF. Eur J Heart Fail 2009;11:802-805.
18. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, Haass M. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-1622.
19. Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007;9:795-801.
20. Kaya Z, Katus HA, Rose NR. Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol 2009;134: 80-88.
21. Adamczyk M, Brashear RJ, Mattingly PG. Circulating cardiac troponin-I autoanti-bodies in human plasma and serum. Ann N Y Acad Sci 2009;1173:67-74.
22. Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem 2005;51:839-847. (Pubitemid 40577920)
23. Leuschner F, Li J, Goser S, Reinhardt L, Ottl R, Bride P, Zehelein J, Pfitzer G, Remppis A, Giannitsis E, Katus HA, Kaya Z. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J 2008;29:1949-1955.
24. Pettersson K, Eriksson S, Wittfooth S, Engstrom E, Nieminen M, Sinisalo J. Auto-antibodies to cardiac troponin associate with higher initial concentrations and longer release of troponin I in acute coronary syndrome patients. Clin Chem 2009;55:938-945.
25. Healey JS, Davies RF, Smith SJ, Davies RA, Ooi DS. Prognostic use of cardiac tro-ponin T and troponin I in patients with heart failure. Can J Cardiol 2003;19: 383-386.
26. La Vecchia L, Mezzena G, Zanolla L, Paccanaro M, Varotto L, Bonanno C, Ometto R. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000;19:644-652.
27. Sundstrom J, Ingelsson E, Berglund L, Zethelius B, Lind L, Venge P, Arnlov J. Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J 2009;30:773-781.
28. Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Raymond K, Woo KS. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;74:502-507.
29. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;113:977-985.
30. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 2001;141:925-932.
31. Hara Y, Hamada M, Shigematsu Y, Suzuki M, Kodama K, Kuwahara T, Hashida H, Ikeda S, Ohtsuka T, Hiasa G, Hiwada K. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 2000;64:365-369.